Tests a device that automatically detects and measures coughs
Tests the C-mo device in people over 2 with cough, to detect coughs.
Plain-language title generated from the registry record
Registry title: Validation of the C-mo System - Cough Monitoring
Key facts
- Where
- Alfena, Amadora, Aveiro, Coimbra, Lisbon, and Porto, PortugalSee the 8 sites
Where in Portugal
- HPAV - Trofa Saúde Hospital de AlfenaAlfena, PortugalTaking people
- HFF - Hospital Professor Doutor Fernando FonsecaAmadora, PortugalTaking people
- Lab3R - Laboratório de Investigação e Reabilitação Respiratória da Escola Superior de Saúde da Universidade de AveiroAveiro, PortugalNo longer taking part
- CHUC - Centro Hospitalar e Universitário de CoimbraCoimbra, PortugalTaking people
- HDE - Hospital Dona EstefâniaLisbon, PortugalTaking people
- NMS Research - Laboratório de Exploração Funcional | FisiopatologiaLisbon, PortugalTaking people
- CHUSJ - Centro Hospitalar Universitário de São JoãoPorto, PortugalTaking people
- ICUFP - Instituto CUF PortoPorto, PortugalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cough Monitoring Medical Solutions
- Trial code
- NCT05989698
- Record updated
- 8 April 2026
- Original description
The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory symptom.Read full original descriptionShow less
Validation of the C-mo System - Cough Monitoring
The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory symptom.
The main questions it aims to answer are:
1. Can C-mo System detect cough events? (automatic cough detection) 2. Can C-mo System characterise cough events? (calculation of cough intensity, identification of cough type and presence of wheeze in detected coughs)
Participants will be asked to:
* Wear the C-mo Wearable device for 24 hours (1 day); * Complete a diary with relevant activities throughout the monitoring period; * Fill-out questionnaires related to coughing frequency and intensity, usability of the device, and impact of cough on quality of life.
Inclusion: Patients aged 2 years or older; Patients with symptoms/complaints of cough; Signed Informed Consent (age ≥ 18 years), signed Informed Consent from the parents/legal representative and the patient (16 and 17 years), or signed Informed Assent and Consent (5 years ≤ age ≤ 15 years).
Exclusion: Presence of musculoskeletal (e.g., severe scoliosis), neurological (e.g., post stroke), cardiac (e.g., unstable angina), cognitive (e.g., dementia) changes, or other significant conditions that hinder the participants from collaborating in the collection of data; Damaged/weakened skin at the C-mo wearable device's placement area (epigastric region); Absence of Informed Consent and/or Assent, as applicable.